Endocrine Abstracts

Aims: Meteorin-like (Metrnl) was recently identified as a novel adipomyokine induced by exercise and cold exposure. Metrnl improves glucose tolerance, increases systemic energy expenditure, induces white adipose browning, and promotes anti-inflammatory gene programs in obese/diabetic mice. However, the relationship of Metrnl with diabetes and cardiometabolic risk variables in humans has not been explored.Methods: In 800 subjects (400 patients with type 2...

Background/Objectives: Although it has been well-established that menopause causes a shift in body fat, thereby eliciting metabolic disturbances in women, there has been no study conducted yet to examine the best obesity parameters to predict the risk of nonalcoholic fatty liver disease (NAFLD) in this population. Thus, the aim of this study was to compare the efficacy of body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) for screening NAFLD accordin...

Background: Given the possible association between dipeptidyl peptidase-4 (DPP-4) inhibitor and risk of diabetic retinopathy (DR), we examined whether DPP-4 inhibitors are beneficial or harmful for DR compared with other glucose-lowering agents.Methods: From a Korean population-based cohort, we identified 67,743 adults with type 2 diabetes treated with oral glucose-lowering agents between 2008 and 2013. Matching (1:1) was done for comparative groups: eve...

Recently, dipeptidyl peptidase-IV (DPP-IV) inhibitor, a major anti-hyperglycaemic agent, has received substantial attention as a possible therapeutic target for inflammatory diseases such as atherosclerosis. However, the direct molecular mechanisms through which DPP-IV inhibitor mediates anti-inflammatory effects in vascular endothelial cells have not been clarified. The effects of the DPP-IV inhibitor, gemigliptin, were analysed in human umbilical vein endothelial cells (HUVE...